Novo Nordisk: How Low Is Too Low? (Downgrade, Technical Analysis)
Novo Nordisk A/S has seen its stock fall sharply, driven by a dramatic slowdown in EPS growth and weak 2026 guidance. A large drop was justified. This article looks at whether it could be overdone. Technical analysis suggests potential support at $36.80 and $29, which would be back to 2018-2020 levels. The company has grown significantly since then.
Here is What to Know Beyond Why Novo Nordisk A/S (NVO) is a Trending Stock
Novo Nordisk (NVO) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Novo Nordisk Rallies 3.6% as Hims & Hers Pulls Compounded Semaglutide
NVO shares jump 3.6% after Hims & Hers halts compounded semaglutide following an FDA warning and patent lawsuit.
Novo Nordisk: Full Kitchen Sink Reset Or Another Shoe Yet To Drop?
Novo Nordisk A/S shares plunged ~25% after sharply lowered 2026 revenue and profit guidance, driven by unexpectedly steep US price declines and competitive pressures. Hims's $49‑per‑month oral Wegovy copycat could have significantly intensified self‑pay competition, but the way events unfolded ultimately provided a modest tailwind for Novo instead. 2025 results were mixed: sales slightly beat and grew +6% YoY, while net income came in a touch below expectations. Global GLP‑1 volume leadership remains intact.
Novo Nordisk, Hims & Hers Health Shares React to Lawsuit
Pharmaceutical giant Novo Nordisk A/S (NYSE:NVO) revealed today it is pursing legal action against Hims & Hers Health Inc (NYSE:HIMS) for alleged patent infringement, after the telehealth giant introduced a weight-loss pill with the same active ingredient as its Wegovy drug -- priced at $149 -- at a much lower starting price of $49.
FDA says Novo Nordisk's TV ad for obesity pill includes 'false or misleading' claims
The Food and Drug Administration said Novo Nordisk's TV advertisement for its newly launched Wegovy pill for obesity included "false or misleading" claims about the medicine's abilities and benefits to patients. In a letter to Novo dated Feb. 5, the FDA requested that the drugmaker take immediate action to address the violations, which could include ceasing all ads containing misleading claims.
FDA says Novo's obesity pill TV Ad is false or misleading
The Food and Drug Administration said a television advertisement for Novo Nordisk's weight loss pill is "false or misleading", according to a letter dated February 5.
5 Things to Know Before the Stock Market Opens
Stock futures are slightly lower this morning after a Friday rally that pushed the Dow above 50,000 for the first time; investors are preparing for a big week of earnings reports and important economic data releases; Novo Nordisk shares are rising after Hims & Hers Health said over the weekend it would pull its compounded semaglutide pill, sending shares of the telehealth company sharply lower; Kroger shares are rising on news the supermarket chain has hired a new CEO; and STMicroelectronics shares are jumping after the European chipmaker announced a deal to supply Amazon. Here's what you need to know today.
Here's why Ozempic stock is soaring today
With its moat of widely popular direct and roundabout weight-loss drugs Ozempic and Wegovy preserved, the Danish medical giant Novo Nordisk (NYSE: NVO) saw its stock price fly early on Monday, February 9.
Novo Nordisk: The Selloff Is A Blessing In Disguise
Novo Nordisk A/S remains a Strong Buy despite a sharp 2026 outlook-driven selloff, with current pricing reflecting excessive market pessimism. NVO faces near-term headwinds from U.S. pricing pressure, patent expirations, and manufacturing ramp-up delays, but underlying free cash flow and profitability remain robust. The Wegovy pill's rapid uptake and first-mover advantage, alongside CagriSema's promising efficacy, position NVO for long-term GLP-1 market leadership.
NVO, LLY Stocks Slide as HIMS Launches $49 Compounded Semaglutide Pill
HIMS shakes up the weight loss market with a $49 compounded semaglutide pill, pressuring Novo Nordisk and Eli Lilly shares and sparking FDA and legal pushback.
Citi flags lingering risks to Novo despite strong weight-loss portfolio
Citi has warned that Novo Nordisk (NYSE:NVO) inability to curb the use of compounded semaglutide may weigh on investor sentiment, despite the strength of its obesity drug portfolio. In a note following Novo's post-results meeting in London, analysts said the launch of a compounded semaglutide pill by Hims & Hers, priced at $49 to $99, posed a challenge to the company's Wegovy pill, which starts at $149.
